IDEAS home Printed from https://ideas.repec.org/a/wly/hlthec/v15y2006i10p1109-1120.html
   My bibliography  Save this article

The economics of diagnosis

Author

Listed:
  • George Laking
  • Joanne Lord
  • Alastair Fischer

Abstract

Any population can be divided into two groups, one with the presence of a given disease or condition, and the other without. Diagnosis consists of using tests to sort the population into these groups. Diagnostic tests use a threshold value of a diagnostic variable to distinguish between disease‐positive and disease‐negative individuals. The analysis of error in diagnostic tests has typically been undertaken using receiver‐operator characteristic (ROC) curves. More recently, economic value of information (VOI) methods have characterised the costs and consequences of testing. This paper develops a new method for economic test evaluation, which we call ROTS analysis. The ROTS curve plots the costs and effects of changing test thresholds, in cost‐effectiveness space. We illustrate the use of our method with a worked example, and show how it can answer three key questions: (1) Is there any test that is worth doing? (2) What is a test's optimum operating point in terms of sensitivity and specificity? (3) If two tests are available, which is best? We contrast the merits of our method with those of established ROC and VOI analysis. We argue that ROTS analysis more clearly reveals the link between changing test thresholds and the cost‐effectiveness of different treatments. Copyright © 2006 John Wiley & Sons, Ltd.

Suggested Citation

  • George Laking & Joanne Lord & Alastair Fischer, 2006. "The economics of diagnosis," Health Economics, John Wiley & Sons, Ltd., vol. 15(10), pages 1109-1120, October.
    • Handle: RePEc:wly:hlthec:v:15:y:2006:i:10:p:1109-1120
    DOI: 10.1002/hec.1114
    as

    Download full text from publisher

    File URL: https://doi.org/10.1002/hec.1114
    Download Restriction: no
    File URL: https://libkey.io/10.1002/hec.1114?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Andre Ament & Rob Baltussen, 1997. "The Interpretation of results of economic evaluation: explicating the value of health," Health Economics, John Wiley & Sons, Ltd., vol. 6(6), pages 625-635, November.
    2. Charles E. Phelps & Alvin I. Mushlin, 1988. "Focusing Technology Assessment Using Medical Decision Theory," Medical Decision Making, , vol. 8(4), pages 279-289, December.
    3. Douglas Coyle & Martin J. Buxton & Bernie J. O'Brien, 2003. "Stratified cost‐effectiveness analysis: a framework for establishing efficient limited use criteria," Health Economics, John Wiley & Sons, Ltd., vol. 12(5), pages 421-427, May.
    4. Dennis G. Fryback & John R. Thornbury, 1991. "The Efficacy of Diagnostic Imaging," Medical Decision Making, , vol. 11(2), pages 88-94, June.
    5. Barbara J. McNeil & James A. Hanley, 1984. "Statistical Approaches to the Analysis of Receiver Operating Characteristic (ROC) Curves," Medical Decision Making, , vol. 4(2), pages 137-150, June.
    6. Eugene M. Laska & Morris Meisner & Carole Siegel & Aaron A. Stinnett, 1999. "Ratio‐based and net benefit‐based approaches to health care resource allocation: proofs of optimality and equivalence," Health Economics, John Wiley & Sons, Ltd., vol. 8(2), pages 171-174, March.
    7. William C. Black, 1990. "The CE Plane," Medical Decision Making, , vol. 10(3), pages 212-214, August.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294, November.
    2. De Donder, Philippe & Bardey, David & Zaporozhets, Vera, 2024. "The Health Technology Assessment Approach of the Economic Value of Diagnostic Tests - A Literature Review," TSE Working Papers 24-1508, Toulouse School of Economics (TSE).
    3. Ariel L Rivas & Mark D Jankowski & Renata Piccinini & Gabriel Leitner & Daniel Schwarz & Kevin L Anderson & Jeanne M Fair & Almira L Hoogesteijn & Wilfried Wolter & Marcelo Chaffer & Shlomo Blum & Tom, 2013. "Feedback-Based, System-Level Properties of Vertebrate-Microbial Interactions," PLOS ONE, Public Library of Science, vol. 8(2), pages 1-16, February.
    4. Markus Eyting, 2020. "A Random Forest a Day Keeps the Doctor Away," Working Papers 2026, Gutenberg School of Management and Economics, Johannes Gutenberg-Universität Mainz.
    5. Oke Gerke & Antonia Zapf, 2022. "Convergence Behavior of Optimal Cut-Off Points Derived from Receiver Operating Characteristics Curve Analysis: A Simulation Study," Mathematics, MDPI, vol. 10(22), pages 1-14, November.
    6. Alexander J. Sutton & Nicola J. Cooper & Steve Goodacre & Matthew Stevenson, 2008. "Integration of Meta-analysis and Economic Decision Modeling for Evaluating Diagnostic Tests," Medical Decision Making, , vol. 28(5), pages 650-667, September.
    7. Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Joanne Lord & George Laking & Alastair Fischer, 2006. "Non‐linearity in the cost‐effectiveness frontier," Health Economics, John Wiley & Sons, Ltd., vol. 15(6), pages 565-577, June.
    2. K. Drakopoulos & R. S. Randhawa, 2021. "Why Perfect Tests May Not Be Worth Waiting For: Information as a Commodity," Management Science, INFORMS, vol. 67(11), pages 6678-6693, November.
    3. Richard M. Nixon & Simon G. Thompson, 2005. "Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 14(12), pages 1217-1229, December.
    4. Andrea Gabrio & Catrin Plumpton & Sube Banerjee & Baptiste Leurent, 2022. "Linear mixed models to handle missing at random data in trial‐based economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 31(6), pages 1276-1287, June.
    5. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    6. Jack Dowie, 2004. "Why cost‐effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 453-459, May.
    7. Laura Levaggi & Rosella Levaggi, 2017. "Rationing in health care provision: a welfare approach," International Journal of Health Economics and Management, Springer, vol. 17(2), pages 235-249, June.
    8. Elisa Sicuri & Silke Fernandes & Eusebio Macete & Raquel González & Ghyslain Mombo-Ngoma & Achille Massougbodgi & Salim Abdulla & August Kuwawenaruwa & Abraham Katana & Meghna Desai & Michel Cot & Mic, 2015. "Economic Evaluation of an Alternative Drug to Sulfadoxine-Pyrimethamine as Intermittent Preventive Treatment of Malaria in Pregnancy," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-23, April.
    9. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
    10. Charles F. Manski, 2022. "Patient‐centered appraisal of race‐free clinical risk assessment," Health Economics, John Wiley & Sons, Ltd., vol. 31(10), pages 2109-2114, October.
    11. Rosella Levaggi & Paolo Pertile, 2020. "Which valued‐based price when patients are heterogeneous?," Health Economics, John Wiley & Sons, Ltd., vol. 29(8), pages 923-935, August.
    12. Xiangjin Shen & Shiliang Li & Hiroki Tsurumi, 2013. "Comparison of Parametric and Semi-Parametric Binary Response Models," Departmental Working Papers 201308, Rutgers University, Department of Economics.
    13. Nadia Yakhelef & Martine Audibert & Gabriella Ferlazzo & Joseph Sitienei & Steve Wanjala & Francis Varaine & Maryline Bonnet & Helena Huerga, 2020. "Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis," Post-Print halshs-03170014, HAL.
    14. Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher, 2012. "Decision-making with Uncertainty: The Value of Information," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 51, Edward Elgar Publishing.
    15. Castillo-Riquelme, Marianela & Chalabi, Zaid & Lord, Joanne & Guhl, Felipe & Campbell-Lendrum, Diarmid & Davies, Clive & Fox-Rushby, Julia, 2008. "Modelling geographic variation in the cost-effectiveness of control policies for infectious vector diseases: The example of Chagas disease," Journal of Health Economics, Elsevier, vol. 27(2), pages 405-426, March.
    16. Gregory S. Zaric, 2008. "Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression," Health Economics, John Wiley & Sons, Ltd., vol. 17(11), pages 1277-1294, November.
    17. James A. Hanley, 1988. "The Robustness of the "Binormal" Assumptions Used in Fitting ROC Curves," Medical Decision Making, , vol. 8(3), pages 197-203, August.
    18. Deon Lingervelder & Hendrik Koffijberg & Ron Kusters & Maarten J. IJzerman, 2021. "Health Economic Evidence of Point-of-Care Testing: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 5(2), pages 157-173, June.
    19. Kämpfen, F.; & Gómez-Olivé, X.; & O’Donnell, O.; & Riumallo Herl, C.;, 2023. "Effectiveness of Population-Based Hypertension Screening: A Multidimensional Regression Discontinuity Design," Health, Econometrics and Data Group (HEDG) Working Papers 23/15, HEDG, c/o Department of Economics, University of York.
    20. Dorte Gyrd‐Hansen, 2003. "Willingness to pay for a QALY," Health Economics, John Wiley & Sons, Ltd., vol. 12(12), pages 1049-1060, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:hlthec:v:15:y:2006:i:10:p:1109-1120. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www3.interscience.wiley.com/cgi-bin/jhome/5749 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.